Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Aop Orphan Pharmaceuticals GmbH
Sponsor

Aop Orphan Pharmaceuticals GmbH

Austria Leopold-Ungar-Platz 2, Döbling, 1190 Vienna, Austria

About the sponsor

Research activity includes essential thrombocythaemia, with a focus on treatment options for patients who are intolerant of, refractory to, or unsuitable for other cytoreductive therapies.

  • Essential thrombocythaemia
  • ELN response criteria
  • Cytoreductive treatment

The clinical interest in this area centres on disease control in a chronic myeloproliferative neoplasm setting.

About Specializations

Aop Orphan Pharmaceuticals GmbH runs clinical trials in conditions such as Pulmonary arterial hypertension, Acute myeloid leukaemia refractory, Acute myeloid leukaemia recurrent, Myelodysplastic syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Acute myeloid leukaemia refractory+2

Recruiting

Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Pulmonary arterial hypertension

Recruiting

Study on the Safety and Tolerability of Treprostinil Sodium for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Treprostinil Sodium
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Pulmonary arterial hypertension

Recruiting

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Essential thrombocythaemia+1

Not recruiting

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.